These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31648294)

  • 1. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Aug; 134(7):636-640. PubMed ID: 31648294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
    Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
    Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
    Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
    Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
    J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
    Morschhauser F; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jäger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
    Nat Med; 2024 Aug; 30(8):2199-2207. PubMed ID: 38830991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
    Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri KV; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY
    N Engl J Med; 2017 Dec; 377(26):2531-2544. PubMed ID: 29226797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.